FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557570409> ?p ?o ?g. }

• W2557570409 abstract "Abstract Background Multiple myeloma (MM) accounts for 10-15% of all newly diagnosed hematological malignancies in the western world and despite recent significant progress in the treatment of MM, it presently remains an incurable disease. Average survival following diagnosis is currently approximately 5 years. Current treatments are effective at reducing malignant cell number (and therefore alleviating symptoms), however a small sub-population of MM cells will survive within the bone marrow milieu and relapse is inevitable. Interactions between the MM and bone marrow mesenchymal stromal cells (BM-MSCs) have been shown to be highly beneficial to the MM cells, protecting them from chemotherapeutic agents and upregulating the expression of genes associated with increased survival and proliferation. We hypothesize that the myeloma cells initiate the re-programming of the BM-MSCs for this very purpose, providing themselves with a more favorable environment. The cytokine MIF (Macrophage Migratory Inhibitory Factor) has been shown to be present in abnormally high levels in many cancer types. Here we show that MIF is aberrantly produced by primary myeloma cells and induces transcriptional changes and cytokine release from the BM-MSC. We also show these signals contribute to MM cell survival and drug resistance. Methods Primary MM and BM-MSC were obtained from patient's bone marrow as previously described. Primary MM cells at 1x106 were co-cultured on confluent autologous BM-MSC. Conditioned media from MM alone, MM/BM-MSC and BM-MSC cultures were collected and analyzed using Proteome Profiler Human XL Cytokine Array and cytokine specific ELISAs. Real-time PCR was used to analyze the changes in BM-MSC transcriptional levels in response to specific cytokine stimulation or inhibition. Recombinant MIF and the MIF inhibitor ISO-1 were used to verify the MM-BMSC findings. Results Here we report that bone marrow, aspirated from MM patients, had a higher level of MIF expression when compared to samples obtained from healthy donors. We examined the cytokine profile in human primary MM monoculture compared to MM cultured with autologous BM-MSC or BM-MSC alone and found that MIF was highly expressed by primary MM and that IL-6 and IL-8 were also increased in MM/BM-MSC co-cultures. RT-PCR confirmed that the majority of MIF transcription within the bone marrow microenvironment occurs within the myeloma cells themselves, with relatively minimal levels found within the bone marrow stromal cells. Next BM-MSCs from MM patients (n=5) were stimulated with recombinant MIF and cytokine release was measured using the XL cytokine array. The results showed that that recombinant human MIF stimulated the release of IL-6 and IL-8 to the media from BM-MSC monocultures. These observed changes were confirmed with the use of cytokine specific ELISA assays. RT-PCR also showed that IL-6 and IL-8 RNA expression were induced in BM-MSCs in response to recombinant MIF. These results confirm that MM derived MIF is instrumental in the transcriptional regulation of IL-6 and IL-8 in BM-MSCs. Next we found that the MIF inhibitor ISO-1 inhibited MM and MIF induced BM-MSC IL-6 and IL-8 RNA expression and cytokine release. Finally we found that MIF inhibition in MM/BM-MSC co-cultures reduced MM survival as well as enhancing the therapeutic potential of proteasome inhibition. Summary Together, these data suggest that MM signals via MIF to initiate the re-programming of the BM-MSCs, which creates a pro-tumoral environment in which MM can thrive and be protected from anti-MM therapeutics. Disclosures No relevant conflicts of interest to declare." @default.
• W2557570409 created "2016-12-08" @default.
• W2557570409 creator A5003662791 @default.
• W2557570409 creator A5032012302 @default.
• W2557570409 creator A5060933992 @default.
• W2557570409 creator A5074010901 @default.
• W2557570409 creator A5074875259 @default.
• W2557570409 date "2015-12-03" @default.
• W2557570409 modified "2023-09-27" @default.
• W2557570409 title "Macrophage Migration Inhibitory Factor Drives Multiple Myeloma IL-6/8 Pro-Survival Signals in the Tumor Microenvironment" @default.
• W2557570409 doi "https://doi.org/10.1182/blood.v126.23.2988.2988" @default.
• W2557570409 hasPublicationYear "2015" @default.
• W2557570409 type Work @default.
• W2557570409 sameAs 2557570409 @default.
• W2557570409 citedByCount "1" @default.
• W2557570409 countsByYear W25575704092017 @default.
• W2557570409 crossrefType "journal-article" @default.
• W2557570409 hasAuthorship W2557570409A5003662791 @default.
• W2557570409 hasAuthorship W2557570409A5032012302 @default.
• W2557570409 hasAuthorship W2557570409A5060933992 @default.
• W2557570409 hasAuthorship W2557570409A5074010901 @default.
• W2557570409 hasAuthorship W2557570409A5074875259 @default.
• W2557570409 hasConcept C104177226 @default.
• W2557570409 hasConcept C142724271 @default.
• W2557570409 hasConcept C16930146 @default.
• W2557570409 hasConcept C198826908 @default.
• W2557570409 hasConcept C202751555 @default.
• W2557570409 hasConcept C203014093 @default.
• W2557570409 hasConcept C2776364478 @default.
• W2557570409 hasConcept C2778690821 @default.
• W2557570409 hasConcept C2779244956 @default.
• W2557570409 hasConcept C2780007613 @default.
• W2557570409 hasConcept C2908647359 @default.
• W2557570409 hasConcept C502942594 @default.
• W2557570409 hasConcept C55493867 @default.
• W2557570409 hasConcept C71924100 @default.
• W2557570409 hasConcept C86803240 @default.
• W2557570409 hasConcept C99454951 @default.
• W2557570409 hasConceptScore W2557570409C104177226 @default.
• W2557570409 hasConceptScore W2557570409C142724271 @default.
• W2557570409 hasConceptScore W2557570409C16930146 @default.
• W2557570409 hasConceptScore W2557570409C198826908 @default.
• W2557570409 hasConceptScore W2557570409C202751555 @default.
• W2557570409 hasConceptScore W2557570409C203014093 @default.
• W2557570409 hasConceptScore W2557570409C2776364478 @default.
• W2557570409 hasConceptScore W2557570409C2778690821 @default.
• W2557570409 hasConceptScore W2557570409C2779244956 @default.
• W2557570409 hasConceptScore W2557570409C2780007613 @default.
• W2557570409 hasConceptScore W2557570409C2908647359 @default.
• W2557570409 hasConceptScore W2557570409C502942594 @default.
• W2557570409 hasConceptScore W2557570409C55493867 @default.
• W2557570409 hasConceptScore W2557570409C71924100 @default.
• W2557570409 hasConceptScore W2557570409C86803240 @default.
• W2557570409 hasConceptScore W2557570409C99454951 @default.
• W2557570409 hasLocation W25575704091 @default.
• W2557570409 hasOpenAccess W2557570409 @default.
• W2557570409 hasPrimaryLocation W25575704091 @default.
• W2557570409 hasRelatedWork W1903562890 @default.
• W2557570409 hasRelatedWork W2000465043 @default.
• W2557570409 hasRelatedWork W2017444994 @default.
• W2557570409 hasRelatedWork W2081616641 @default.
• W2557570409 hasRelatedWork W2097041710 @default.
• W2557570409 hasRelatedWork W2367697913 @default.
• W2557570409 hasRelatedWork W2384057116 @default.
• W2557570409 hasRelatedWork W2414755533 @default.
• W2557570409 hasRelatedWork W2418772561 @default.
• W2557570409 hasRelatedWork W2554552323 @default.
• W2557570409 hasRelatedWork W2582947460 @default.
• W2557570409 hasRelatedWork W2585296195 @default.
• W2557570409 hasRelatedWork W2585858009 @default.
• W2557570409 hasRelatedWork W2591507538 @default.
• W2557570409 hasRelatedWork W2624792657 @default.
• W2557570409 hasRelatedWork W2769668547 @default.
• W2557570409 hasRelatedWork W2980378344 @default.
• W2557570409 hasRelatedWork W2981656835 @default.
• W2557570409 hasRelatedWork W314207901 @default.
• W2557570409 hasRelatedWork W3185425119 @default.
• W2557570409 isParatext "false" @default.
• W2557570409 isRetracted "false" @default.
• W2557570409 magId "2557570409" @default.
• W2557570409 workType "article" @default.